By detailing the clinical decision-making process, pharmacological strategies, and treatment outcomes, this report aims to offer practical guidance for the management of complex multidrug regimens and individualized pharmacotherapy in patients with CSF1R-related leukoencephalopathy following hematopoietic stem cell transplantation (HSCT). This evidence concerns the gene CSF1R and Leukoencephalopathy.